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Introduction
The hepatitis D virus (HDV) also known as hepatitis
delta virus is a single stranded defective RNA virus
consisting of 1679 nucleotides.1-3 For its penetration into
hepatocytes and assembly of virion it needs the help of
hepatitis B virus (HBV) that provides the viral coat with the
surface antigen.2,4,5 HDV can cause both rapid progression
of already existing HBV Hepatitis and fulminant hepatitis.6
Infection by HDV can be caused either as a co-
infection in individuals with HBV or as a superinfection in
chronic HBV carriers.4,7,8 Individuals having HBV-HDV
co-infection may have more severe acute disease and higher
risk of fulminant hepatitis.6,7,9,10 Persons suffering from
HDV superinfection have more risks of progressing rapidly
to cirrhosis than the individuals suffering from HBV
monoinfection.4,7,9,10 It is observed that most of individuals
infected with HDV develops the chronic form of the disease
and in approximately 80% of these individuals the chronic
Hepatitis D progresses to cirrhosis within 5-10 years.1
Another important feature of chronic hepatitis D is that it
can give rise to hepatocellular carcinoma in the infected
individuals.11
Chronic hepatitis D treatment is presently
unsatisfactory and the only agent which has some effect on
the chronic infection is alpha interferon.2,7,8,10,12,13Although
HBV vaccine is useful in preventing both HBV and HDV,7
there is no effective measure to prevent HDV superinfection
in HBV carriers.
HDV is an infection present worldwide and in all age
groups but its distribution is not uniform and the general
pattern of its distribution corresponds to that of the
prevalence of chronic HBV infection.14 There are around
350 million carriers of HBV around the world and 18
million people have been infected with the virus.7 An
important trend in the worldwide HDV infection is that a
global decline in the prevalence of hepatitis D infection has
been observed. This is true for both acute and chronic forms
of the disease.8
Mumtaz et al noted a prevalence of 16.6% in HBsAg
positive patients from different areas of Pakistan.15 The aim
of this study was to estimate the prevalence of hepatitis D in
hepatitis B surface antigen (HBsAg) positive patients
visiting the liver clinics.
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Abstract
Objective: To estimate the prevalence of hepatitis D in HBsAg (hepatitis B surface antigen) positive patients
visiting liver clinics.
Methodology: All HbsAg positive patients who had visited two liver clinics; in Karachi and in Jacobabad, from
October 2007 to March 2008, were included in this study.  These patients were tested for HBV DNA and HDV
RNA by PCR technique, HBeAg and anti-HDV. Clinical status of the patients was evaluated by examination,
routine biochemical tests and ultrasound.
Results: Total numbers of patients included in the study were 362 comprising of 151 patients from the clinic in
Jacobabad and 211 from Karachi. The patients ranged from 4 to 70 years age (mean age 29.75 ±11.27). Out of
the total patients 297 (82%) were males. All the patients were screened for HDV antibody out of which 212
(58.6%) tested positive. Total 65 anti-HDV positive patients were tested for the HDV RNA by PCR, out of which
30 (46.2%) tested positive for the virus. Three hundred and forty (340) patients were screened for HBeAg, out
of which 71 (20.9%) tested positive. Three hundred and seven patients were screened for HBV DNA by PCR,
out of which 88 (28.7%) were positive for the virus. HBV DNA was positive in 16.2% of HbeAg negative patients
(pre-core mutants). The frequency of positive HDV antibody was 69.23% in patients from Kashmore, 67% in
Jacobabad, 65.4% in Jaffarabad, 65.21% in Quetta, 60% in Naseerabad, 36.58% in Karachi, 58.33% in other
areas of Balochistan and 60.71% in other areas of Sindh. Positive HDV antibody status was associated with
more severe and advanced disease (p<0.0001)
Conclusion: This data shows extremely high prevalence of hepatitis D in the referred patients from some areas
of Southern Pakistan. Effective preventive measures are the need of the hour and Pakistan may be considered
as one of the areas of highest HDV prevalence around the globe (JPMA 59:434; 2009).
Methods
This study was conducted at two centres, Medicare
Clinic in Karachi and Imam Clinic in Jacobabad. Along with
the local residents, a significant number of patients from
different parts of Sindh and Balochistan also visit these clinics
for consultation. 
The study included 362 HBsAg positive patients who
visited these two liver clinics from October 2007 to March
2008. These were further screened for any activity of hepatitis
B by hepatitis B e antigen (HBeAg) and HBV DNA by real
time polymerase chain reaction (PCR). The patients were
further screened for associated hepatitis C and D by doing
antibody tests. These serological tests were performed on third
generation ELISA AXSym Abbott (6.0) employing micro
particle enzyme immunoassay. The patients who were anti-
HDV positive were tested for HDV RNA by PCR. Other
investigations that were ordered include complete blood count,
serum alpha-fetoprotein, serum albumin and an ultrasound
examination of the abdomen. 
The clinical status of the patients was determined by
examination, routine biochemical tests and ultrasound
abdomen examination. Patients were divided into four
categories namely (i) carrier of HBsAg (ii) active hepatitis (iii)
compensated cirrhosis (iv) decompensated cirrhosis. The
patients were labeled as clinicaly compensated cirrhosis on the
basis of clinical and ultrasound findings suggestive of cirrhosis
(nodular surface, firm consistency, blunt liver edge, altered
echotexture, dilated portal vein and splenomegaly) and
evidence of hypersplenism (platelets < 150 000/mm3).
Decompensated cirrhosis was defined as presence of ascites,
encephalopathy, variceal bleeding and hepatorenal syndrome.
A standardized proforma was completed for each patient that
includes age, sex, district of residence and clinical status of
patient. All the data analysis was carried out using the SPSS
software version 15.0.
Results
The total number of patients included in the study was
362 comprising of 151 patients from the clinic in Jacobabad
and 211 from Karachi. The patients ranged from 4 to 70 years
of age (mean age 29.75 ± 11.27) and 297 (82%) of the patients
were male. Out of the total patients who visited these clinics,
97 (26.8%) were the residents of Jacobabad, 82 (22.7%) from
Karachi, 55 (15.2%) from Jaffarabad, 35 (9.7%) from
Nasirabad, 26 (7.2%) from Kashmore, 23 (6.4%) from Quetta
and remaining 44 (12.1%) from other parts of Sindh,
Balochistan and Punjab.
All the patients were screened for HDV antibody, out of
which 212 (58.6%) tested positive for the virus. Total 65
patients were screened for the HDV RNA by PCR out of which
30 (46.2%) tested positive for the virus.
Three hundred and forty (340) patients were screened
for HBeAg out of which 71 (20.9%) tested positive for
HBeAg. Three hundred and seven patients were screened for
HBV DNA by PCR out of which 88 (28.7%) tested positive for
the virus. Out of 269 patients that tested negative for the
HBeAg, 229 were screened for HBV DNA by PCR of which
37 (16.2% ) tested positive for the HBV DNA by PCR and
represented the pre-core mutant form of the disease. Out of the
71 patients who tested positive for HBeAg, 61 were screened
for HBV DNA by PCR out, of which 48 (78.7%) tested
positive.
The prevalence of the HDV antibody was 69.23% in
Kashmore, 67% in Jacobabad, 65.4% in Jaffarabad, 65.21% in
Quetta, 60% in Nasirabad, 36.58% in Karachi, 58.33% in other
areas of Balochistan and 60.71% in other areas of Sindh as
shown in Table-1.
One hundred and sixteen (116) of the total patients
were screened for the hepatitis C virus antibody (HCV Ab) out
of which 18 (15.5%) tested positive.
Of the total patients visiting the clinics, 284 (78.5%)
were clinically non-cirrhotic and 78 (21.5%) were cirrhotic
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Table-1: Prevalence of HDV patients visiting clinics from different areas.
Area HDV Ab +ve Patients Total Patients Percentage
Jacobabad 65 97 67%
Karachi 30 82 36.58%
Jafferabad 36 55 65.4%
Naseerabad 21 35 60%
Kashmore 18 26 69.23%
Quetta 15 23 65.21%
Other Areas
of Sindh 17 28 60.71%
Other Areas
of Balochistan 7 12 58.33%
Southern Punjab 3 4 75%
Table-2: Effect of HDV antibody status on disease severity.
Clinical Status Total Patients HDV Ab Positive HDV Ab Negative p-value*
Carrier of HBV 143 53 90 <0.0001
Active Hepatitis B 141 95 46 <0.0001
Compensated Cirrhosis 34 29 5 <0.0001
Decompensated Cirrhosis 44 35 9 <0.0001
* p-values by Pearson Chi-Square Test.
comprising of 44 (12.2%) patients with decompensated
cirrhosis and 34 (9.4%) with compensated cirrhosis. Positive
HDV antibody status was associated with more severe and
advanced disease (p<0.0001) (Table-2 & Figure).
Discussion
This study shows an extremely high prevalence of
HDV infection in some pockets of Southern Pakistan. The
majority of the high prevalence areas come from rural areas of
Sindh and Balochistan. However, HDV prevalence is even not
low in urban cities like Karachi and Quetta, as indicated by our
results. Although the sample size that showed these results is
not too large as the patients included in the study are those who
visited the liver clinic. However, this study provides a new data
from places like Kashmore, Jacobabad, Jaffarabad and
Naseerabad which are highly HDV prevalent and were not
previously documented in any epidemiological survey. In the
light of current available data these areas can be regarded as the
regions with highest prevalence of HDV infection in Pakistan.
Figure 1 and table 2 shows the comparison of the clinical status
of HDV positive and negative patients.
We observed higher HDV prevalence in young males.
This is in corroboration with the findings of a previously done
epidemiological survey in Pakistan.15 This could be due to the
higher frequency of injectible drug abuse and the use of
contaminated needles for therapeutic injections.16 Sexual
transmission is another possible explanation for this high
prevalence.15
In Pakistan according to an epidemiological survey
that included 8721 HBV patients over 14 years of age and
tested for anti-HDV antibody from all over the country, the
HDV prevalence was 16.6%. The study added that a large belt
of rural area exists in the middle of the country with a high
prevalence of HDV.15Our study showed an overall prevalence
of 58.6% which is much higher than the 7 year old data.
However, this may be because the patients of this study were
from areas of higher prevalence and also visiting a specific
clinic which may not reflect the true disease prevalence.
As mentioned before, an overall decline in the
worldwide HDV infection has been observed.8 This
decreasing trend is the result of global vaccination and
hence HDV infection is expected to be decrease with
time.17-19 Research results in India have shown a decline in
HDV infection similar to the trend seen world wide.18 The
same trend is also observed in Turkey.19 However, in a
developing country like Pakistan due to lack of resources
and therefore lack of preventive strategies, HDV prevalence
seems to be on the rise.
References
1. Wiwanitkit V. Predicted binding affinity of candidate HDV epitope: a
bioinformatics study. Ann Hepatol 2007; 6:108-10.
2. Koytak ES, Yurdaydin C, Glenn JS. Hepatitis d. Curr Treat Options
Gastroenterol 2007; 10:456-63.
3. Greeve J, Hartwig D, Windler E, Greten H. Requirements for editing in the
genomic RNA of hepatitis delta virus. Biochimie 1994; 76:1209-16.
4. Ryu WS, Bayer M, Taylor J. Assembly of hepatitis delta virus particles. J Virol
1992; 66:2310-5.
5. Shih HH, Jeng KS, Syu WJ, Huang YH, Su CW, Peng WL, et al. Hepatitis B
surface antigen levels and sequences of natural hepatitis B virus variants
influence the assembly and secretion of hepatitis d virus. J Virol 2008;
82:2250-64.
6. Monjardino JP, Saldanha JA. Delta hepatitis. The disease and the virus. Br
Med Bull 1990; 46:399-407.
7. Fonseca JC. [Hepatitis D] Rev Soc Bras Med Trop 2002; 35:181-90.
8. Hsieh TH, Liu CJ, Chen DS, Chen PJ. Natural course and treatment of
hepatitis D virus infection. J Formos Med Assoc 2006; 105:869-81.
9. Rizzetto M. Hepatitis delta virus (HDV) infection and disease. Ric Clin Lab
1989; 19:11-26.
10. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M,
Boyer N, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis
delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006;
44:728-35.
11. Hadziyannis SJ. Review: Hepatitis delta. J Gastroenterol Hepatol 1997;
12:289-98.
12. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Resolution of
chronic delta hepatitis after 12 years of interferon alfa therapy.
Gastroenterology 1999; 117:1229-33.
13. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat 2005;
12:2-9.
14. World Health Organization. Department of Communicable Disease Surveillance
and Response. Hepatitis Delta.
http://www.who.int/csr/disease/hepatitis/HepatitisD_whocdscsrncs2001_1.pdf.
15. Mumtaz K, Hamid SS, Adil S, Afaq A, Islam M, Abid S, et al. Epidemiology
436 J Pak Med Assoc
Figure: Bar Chart comparing clinical status of HDV antibody
positive and negative patients.
and clinical pattern of hepatitis delta virus infection in Pakistan. J
Gastroenterol Hepatol 2005; 20:1503-7.
16. Luby SP, Qamaruddin K, Shah AA, Omair A, Pasha O, Khan AJ, et al. The
relationship between therapeutic injections and high prevalence of hepatitis C
infection in Hafizabad, Pakistan. Epidemiol Infect 1997; 119: 349-56.
17. Al-Traif I, Ali A, Dafalla M, Al-Tamimi W, Qassem L. Prevalence of hepatitis
delta antibody among HBsAG carriers in Saudi Arabia. Ann Saudi Med 2004;
24:343-4.
18. Chakraborty P, Kailash U, Jain A, Goyal R, Gupta RK, Das BC, et al.
Seroprevalence of hepatitis D virus in patients with hepatitis B virus-related
liver diseases. Indian J Med Res 2005; 122:254-7.
19. De?ertekin H, Yalçin K, Yakut M. The prevalence of hepatitis delta virus
infection in acute and chronic liver diseases in Turkey: an analysis of clinical
studies. Turk J Gastroenterol 2006; 17:25-34.
Vol. 59, No. 7, July 2009 437
